GeneDx Shares Skyrocket 50% Today on Profit Milestone and Surge in Genomic Growth

GuruFocus.com
2024-10-29
GeneDx Holdings3.88%盘后

GeneDx (NASDAQ:WGS) is making waves as its stock skyrocketed nearly 50% today, hitting a 52-week high after delivering standout Q3 2024 results. Revenue surged to $76.6 million, marking a 52% YoY increase, with exome and genome testing revenue soaring 77% to $60 million. Driving this growth is GeneDx's steady expansion across state Medicaid programs, now covering 30 states, a shift that's boosting its standing in clinical genomics. With adjusted gross margins widening to 64%, up from last year's 48%, GeneDx has positioned itself not just for profitability but as a front-runner in the genomic testing space.

  • Warning! GuruFocus has detected 5 Warning Signs with WGS.

CEO Katherine Stueland pointed to an unshakeable growth trajectory as the company lifted its 2024 revenue guidance to $284-$290 million, with gross margins expected to hit 62%. By strategically integrating its genome diagnostics across critical pediatric and neonatal care, GeneDx is delivering tangible results that solidify its role in transforming healthcare standards. Beyond just numbers, this momentum reflects GeneDx's commitment to patient impact and industry leadership.

Looking ahead, GeneDx isn't slowing down. Plans are underway to launch the Epic Aura platform in 2025, streamlining genome testing across major U.S. health systems, a move that will set new industry benchmarks. CFO Kevin Feeley underscored GeneDx's disciplined yet aggressive growth strategy, combining financial resilience with innovation in genomic newborn screening and rare disease research. The surge in share price underscores investor confidence that GeneDx is on the path to becoming a cornerstone in genomic diagnostics and patient care, with further growth primed for 2025 and beyond.

This article first appeared on GuruFocus.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

no data

没有相关数据

如果下载按钮点击无跳转,请点击右上角菜单选择 “在浏览器打开”